



Press release from Emotra AB (publ)

Göteborg, June 3, 2020

Communiqué from the Annual General Meeting of EMOTRA AB (publ)

The Annual General Meeting of EMOTRA AB (publ) was held today, June 3, 2020. The resolutions, summarised below, were all adopted with the necessary majority.

Net income appropriation

The AGM approved the Board's proposal for allocation of the Company's loss as presented in the annual report. Furthermore, the AGM decided that no dividend be paid for the financial year 2019. The AGM also granted the Board of Directors and the CEO discharge for the financial year 2019.

Determination of the number of board members and deputy members, as well as the number of accountants and deputy accountants; Determination of the fees to be paid to the board members and accountant

The AGM decided that the Board shall be composed of four regular members and no deputy members and set the annual compensation for the Board to 165,550 SEK, whereof 70,950 SEK for the chairperson (1.5 x the price basic amount) and 47,300 SEK (1 price basic amount) each for the two external/independent regular board members. Furthermore, the AGM decided that one auditor and one deputy auditor shall be appointed, and that they shall be compensated in line with usual charges and upon presentation of approved invoice.

Election of Board of Directors and accountant

The AGM decided that Claes Holmberg, Jan Pilebjer*, Anna Sjörs* and Lars-Håkan Thorell shall be re-elected as regular board members. Furthermore, the AGM resolved to re-elect Thomas Nilsson as the Company's auditor and Marcus Hellsten as deputy auditor.

** independent board members, according to the regulatory framework of Spotlight Stockmarket*

EMOTRA AB (publ)
THE BOARD OF DIRECTORS

For further information, please contact: Daniel Poté, CEO, Telephone: +46 73 234 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

EMOTRA AB, AstraZeneca BioVentureHub, Pepparedsleden 1
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, www.emotra.se